Overview

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2026-10-12

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to measure the efficacy (Myeloma response) of subcutaneous (SC) isatuximab treatment in combination with carfilzomib and dexamethasone in adult participants with RRMM having received 1 to 3 prior lines of therapy. After confirmation of the feasibility of SC isatuximab by manual administration, patient will be randomized to 1 of the 2 delivery method of SC isatuximab.

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate